{"disease":{"id":"intra-abdominal-infection","name":"intra abdominal infection"},"drugs":{"marketed":[{"drug_id":"zavicefta-ceftazidime-avibactam","indication_name":"Complicated intra-abdominal infections (cIAI) caused by certain susceptible bacteria.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavicefta, Ceftazidime-Avibactam","generic_name":"zavicefta-ceftazidime-avibactam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial cell wall synthesis","drug_class":"Cephalosporin antibiotic and beta-lactamase inhibitor combination","quality_score":55,"revenue":"638","mechanism":""},{"drug_id":"technetium-tc-99m-exametazime","indication_name":"Localization of intra-abdominal infection and inflammatory bowel disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceretec","generic_name":"TECHNETIUM TC 99M EXAMETAZIME","company_name":"GE HealthCare","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin-sodium","indication_name":"Intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFOXITIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1200962","indication_name":"Complicated Intra-abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFEPIME HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"relebactam","indication_name":"Complicated Intra-abdominal Infections (cIAI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Recarbrio","generic_name":"RELEBACTAM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Renal Dehydropeptidase Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":"Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria."},{"drug_id":"ceftazidime","indication_name":"Intra-abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"ampicillin-sodium","indication_name":"Intra-Abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AMPICILLIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3989564","indication_name":"Intra-abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOBRAMYCIN SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"piperacillin-and-tazobactam","indication_name":"Intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Piperacillin And Tazobactam","generic_name":"Piperacillin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial cell wall; beta-lactamase enzyme","drug_class":"Penicillin-class antibacterial with beta-lactamase inhibitor","quality_score":64,"revenue":null,"mechanism":"Piperacillin and tazobactam is an antibacterial drug combining a penicillin with a beta-lactamase inhibitor."},{"drug_id":"cefoxitin","indication_name":"Intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Escherichia coli","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Citrobacter freundii","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Enterobacter cloacae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Klebsiella oxytoca","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Enterococcus faecalis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Enterococcus faecium","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."}],"pipeline":[],"offLabel":[],"totalMarketed":18,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04094818","title":"TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis","phase":"","overall_status":"COMPLETED","enrollment_count":1441,"lead_sponsor_name":"Inflammatix","has_results":false},{"nct_id":"NCT05148702","title":"EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1166,"lead_sponsor_name":"Sarah Cockayne","has_results":false},{"nct_id":"NCT03678298","title":"Italian Register for the Study of Complicated Intra-Abdominal Infections","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"World Society of Emergency Surgery","has_results":false},{"nct_id":"NCT06633718","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":786,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06828874","title":"A Study of Levornidazole Disodium Phosphate for Injection vs. Ornidazole in Treatment of Postoperative Intra-Abdominal Infections Caused by Anaerobic Bacteria","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":696,"lead_sponsor_name":"Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd","has_results":false},{"nct_id":"NCT03358576","title":"Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":674,"lead_sponsor_name":"Iterum Therapeutics, International Limited","has_results":true},{"nct_id":"NCT05733104","title":"A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03744741","title":"HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study","phase":"","overall_status":"COMPLETED","enrollment_count":585,"lead_sponsor_name":"Inflammatix","has_results":false},{"nct_id":"NCT02784704","title":"Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Tetraphase Pharmaceuticals, Inc","has_results":true},{"nct_id":"NCT01445678","title":"Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":494,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT01069900","title":"Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":458,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT03580733","title":"Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":448,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT06304779","title":"The Effect of Continuous Intravenous Infusion of Lidocaine on PPCs and Prognosis in Emergency Surgical Patients With IAI","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":428,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT03329092","title":"A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":422,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01506271","title":"Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":351,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07172451","title":"Gelaspan vs Crystalloid Therapy in Sepsis","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":318,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT05127109","title":"The PASTDUe Nutrition Ecosystem Project (PASTDUe)","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05549076","title":"Hellenic Registry for cIAIs (HERCO-II)","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Maximos Frountzas","has_results":false},{"nct_id":"NCT03830333","title":"Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":268,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05487586","title":"Real-World Study of Ceftazidime Avibactam in China","phase":"","overall_status":"TERMINATED","enrollment_count":220,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT00752219","title":"Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03544203","title":"Multicentre Observational Study on Community Acquired Intraabdominal Infections Management","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT03997929","title":"Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2)","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT05147870","title":"Outcome After Laparoscopic Surgery for Peptic Ulcer Perforation","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Chang Wei-Jung","has_results":false},{"nct_id":"NCT04612413","title":"A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"Enlivex Therapeutics Ltd.","has_results":false},{"nct_id":"NCT03482245","title":"The Role of Circadian Clock Proteins in Innate and Adaptive Immunity","phase":"NA","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT05905055","title":"P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Meiji Seika Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT01147640","title":"Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT01789905","title":"Tygacil Drug Use Investigation","phase":"","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03061500","title":"Prognostic Value of Proadrenomedullin in Intra-abdominal Sepsis","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Instituto de Investigación Hospital Universitario La Paz","has_results":false},{"nct_id":"NCT07268560","title":"Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Sir Run Run Shaw Hospital","has_results":false},{"nct_id":"NCT03862378","title":"Prediction of Intra-abdominal Infectious Complication by Drainage Fluid Analysis","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06838585","title":"Intra-Abdominal Sepsis and Relationship Between Cumulative Fluid Balance and Serum Sodium and Chloride Levels and In-Hospital Mortality","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Clinical Center of Vojvodina","has_results":false},{"nct_id":"NCT02739997","title":"Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06901544","title":"Capillary Leak Index as a Prognostic Indicator for Post-Operative Abdominal Sepsis in Critically Ill Patients","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Ain Shams University","has_results":true},{"nct_id":"NCT07130799","title":"Innate Immune Response Monitoring Via Monocyte HLA-DR in Severe Intra-abdominal Infections at Risk of Fungal Infection","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT03217136","title":"MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07005258","title":"Diagnostic Performance of the CandID PLUS PCR for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients","phase":"","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT03293485","title":"Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02475733","title":"Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07207291","title":"Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"Joincare Pharmaceutical Group Industry Co., Ltd","has_results":false},{"nct_id":"NCT04882085","title":"Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04927312","title":"Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04335539","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Shionogi","has_results":true},{"nct_id":"NCT02655419","title":"Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06794541","title":"A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Tetraphase Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT03265834","title":"CABI: Antibiotic Duration for Complicated Intra-ABdominal Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT04519086","title":"The Optimization of a Low-dose CT Protocol in Patients With Suspected Uncomplicated Acute Appendicitis and BMI >30","phase":"NA","overall_status":"SUSPENDED","enrollment_count":30,"lead_sponsor_name":"Turku University Hospital","has_results":false},{"nct_id":"NCT05187871","title":"Study for Rapid Diagnosis of Postoperative Abdominal Infection","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07093203","title":"Rezafungin Peritoneal Diffusion for Intra-abdominal Candidiasis","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}